The efficacy of glycemic control with continuous glucose monitoring on atheroma progression: rationale and design of the Observation of Coronary Atheroma Progression under Continuous Glucose Monitoring Guidance in Patients with Type 2 Diabetes Mellitus (OPTIMAL)

Yu Kataoka¹, Kiminori Hosoda², Hisashi Makino³, Masaki Matsubara³, Miki Matsuo⁴, Yoko Ohata², Ryo Koezuka², Tamiko Tamanaha², Tsutomu Tomita², Kyoko Honda-Kohmo², Michio Noguchi², Cheol Son², Kunihiro Nishimura¹, Yasuhide Asaumi¹, Yoshihiro Miyamoto⁴, Teruo Noguchi¹, Satoshi Yasuda¹

¹Department of Cardiovascular Medicine, ²Division of Atherosclerosis and Diabetes, ³Department of Statistics and Data Analysis, ⁴Division of Preventive Cardiology, National Cerebral & Cardiovascular Center, Osaka, Japan

Contributions: (I) Conception and design: Y Kataoka, H Makino, K Hosoda; (II) Administrative support: K Hosoda; (III) Provision of study materials or patients: Y Kataoka, H Makino, K Hosoda; (IV) Collection and assembly of data: Y Kataoka, H Makino; (V) Data analysis and interpretation: K Nishimura; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors.

Correspondence to: Kiminori Hosoda, MD, PhD. Division of Atherosclerosis and Diabetes, National Cerebral & Cardiovascular Center, Fujishirodai 5-7-1, Suita, Osaka, Japan. Email: kiminorihosoda@ncvc.go.jp.

Background: Patients with type 2 diabetes mellitus (T2DM) are high-risk subjects who more frequently have micro- and macrovascular diseases including coronary artery disease (CAD). Since impaired glycemic homeostasis directly influences the formation and propagation of atherosclerotic plaques, optimal management of glycemic status is required for the prevention of diabetic atherosclerosis. Continuous glucose monitoring (CGM) provides not only average glucose level but also the degree of glucose fluctuation and hypoglycemia. Given the association of glycemic variability with diabetic macrovascular diseases, CGM-based glycemic management could favorably modulate glycemic fluctuation, thereby potentially modifying atheroma burden in T2DM subjects. To test this hypothesis, the Observation of Coronary Atheroma Progression under Continuous Glucose Monitoring Guidance in Patients with Type 2 Diabetes Mellitus (OPTIMAL) study has been designed (Japan Registry of Clinical Trials: jRCT1052180152, University Hospital Medical Information Network Clinical Trial Registry UMIN000036721).

Methods: The OPTIMAL is a single-center, randomized trial to evaluate the efficacy of CGM-based glycemic control on atheroma progression in T2DM patients with CAD by using serial intravascular ultrasound (IVUS) and near-infrared spectroscopy (NIRS) imaging. A total of 90 eligible subjects will be randomized 1:1 into two groups to receive either CGM-based glycemic control or HbA1c-based glycemic management. Coronary angiography and NIRS/IVUS imaging is repeated at the end of the assigned treatment period.

Results: The primary endpoint is the normalized absolute change in total atheroma volume (TAV) from baseline to 12 months. The secondary endpoints include (I) the absolute change in percent atheroma volume, (II) the percent change in lipid core burden index, (III) the change in coefficient variance measured by CGM, (IV) the change in atherogenic markers (high-density lipoprotein functionality, proprotein convertase subtilisin/kexin type 9 and fatty-acid binding proteins), and (V) the frequency of hypoglycemia. Safety will also be evaluated.

Conclusions: The collaboration of CGM use with serial NIRS/IVUS imaging will enable to compare atheroma progression rate under CGM-based glycemic management and HbA1c-based approach.
Introduction

Current therapeutic guidelines recommend achieving glycated hemoglobin HbA1c <7.0% to prevent macrovascular diseases in type 2 diabetes mellitus (T2DM) patients (1,2). However, several randomized controlled trials demonstrated that stricter control of HbA1c did not necessarily improve their cardiovascular outcomes (3-5). In particular, intensive lowering HbA1c elevates a risk of hypoglycemia which has been shown to associate with higher mortality (5). These observations suggest the limitation of HbA1c-based glycemic control for the prevention of diabetic macrovascular diseases. Given that HbA1c reflects average blood glucose in the past 1–2 months but not serial changes in glucose level including hypoglycemia, the another approach enabling real-time accurate monitoring of glucose level is required.

Continuous glucose monitoring (CGM) continuously evaluates glucose levels in the interstitial fluid, which provides not only average glucose level but also the degree of glucose fluctuation and hypoglycemia (6). Since glucose fluctuation and hypoglycemia have been shown to induce pro-atherogenic responses (7), we hypothesize that CGM-based glycemic management could favorably modulate glycemic fluctuation, which slows progression of coronary atherosclerosis, an important substrate for macrovascular disease in T2DM subjects. Therefore, the current study is designed to evaluate the effect of glucose control with CGM guidance on progression of coronary atherosclerosis in T2DM patients with coronary artery disease (CAD) who will require percutaneous coronary intervention (PCI).

Methods

Study design

OPTIMAL is an investigator-initiated, prospective, randomized, parallel-group, single center trial (jRCT1052180152, UMIN000036721) (Table S1). This study evaluates the efficacy of glucose lowering under CGM guidance on progression of coronary atherosclerosis in T2DM patients with coronary artery disease (CAD) who will require percutaneous coronary intervention (PCI). Enrollment of 90 patients is planned at National Cerebral & Cardiovascular Center in Japan.

T2DM patients hospitalized for stable CAD requiring PCI are potentially eligible. Screening is performed prior to the scheduled PCI. In patients who fulfill all eligibility criteria, written informed consent will be obtained by primary or co-investigators. Study participants are randomly assigned to either CGM-based glucose management or HbA1c-based glucose management. Randomization is stratified according to age, gender, high-intensity statin use, HbA1c and LDL-C levels by co-investigator (Nishimura K). Randomization will be stratified by age, gender, HbA1c, LDL-C and high-intensity statin use. Clinical visits are scheduled at 1, 3, 6, 9 and 12 months after the completion of PCI. In the CGM-based glucose management group, CGM and HbA1c measurement will be conducted at baseline and 3, 6, 9 and 12 months following PCI. In the HbA1c-based glucose management group, CGM will be done at baseline and 12 months in a similar fashion. The study schedule is summarized by Table 1.

Inclusion and exclusion criteria

Inclusion criteria are summarized in Table 2. Briefly, eligible subjects should have CAD requiring elective PCI. Mild stenosis needs to exist within non-culprit major coronary artery. Since the current study enroll subjects who need glucose lowering therapy to achieve HbA1c <7.0%, HbA1c at screening should be between 7.0% and 10.0%. In T2DM subjects who already receive sulphonylurea, nateglinide and/or insulin at screening, baseline HbA1c should be below 10.0% and the lowest cut-off is not set. Due to an elevated risk of hypoglycemia under these anti-diabetic agents, subjects with HbA1c <7.0% may have hypoglycemic events which require adequate glycemic control.

The main exclusion criteria are listed in Table 3. Non-culprit vessel with its severe tortuosity and/or calcification
Table 1 The schedule of enrolment, interventions, and assessments

<table>
<thead>
<tr>
<th>Enrolment, interventions, and assessments</th>
<th>Study period</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Visit 1 (enrollment)</td>
</tr>
<tr>
<td>Eligibility screen</td>
<td>√</td>
</tr>
<tr>
<td>Randomization</td>
<td></td>
</tr>
<tr>
<td>Vital signs</td>
<td>√</td>
</tr>
<tr>
<td>Biochemistry data (HbA1c, glucose level, lipid profiles)</td>
<td>√</td>
</tr>
<tr>
<td>Urine test</td>
<td></td>
</tr>
<tr>
<td>Biomarkers (PCSK9, HDL efflux, FABP4/5)</td>
<td></td>
</tr>
<tr>
<td>CGM use</td>
<td></td>
</tr>
<tr>
<td>CGM group</td>
<td>√</td>
</tr>
<tr>
<td>HbA1c group</td>
<td></td>
</tr>
<tr>
<td>Electrocardiogram</td>
<td></td>
</tr>
<tr>
<td>Chest X-ray</td>
<td></td>
</tr>
<tr>
<td>Echocardiography</td>
<td></td>
</tr>
<tr>
<td>Coronary angiography</td>
<td></td>
</tr>
<tr>
<td>Intravascular imaging</td>
<td></td>
</tr>
<tr>
<td>Concomitant drug use</td>
<td>√</td>
</tr>
<tr>
<td>AEs</td>
<td>√</td>
</tr>
<tr>
<td>Discontinuation</td>
<td>√</td>
</tr>
<tr>
<td>Outcomes</td>
<td></td>
</tr>
</tbody>
</table>

CGM, continuous glucose monitoring; AEs, adverse effects.

Table 2 Inclusion criteria

Male of female between 20 and 80 years of age
Type 2 diabetic patients with coronary artery disease who require PCI
The presence of mild stenosis in the non-target vessel (% diameter stenosis between 10-50%)
7.0% ≤ HbA1c ≤ 10.0%
HbA1c ≤ 10.0% in subjects who receive insulin, sulfonylurea or nateglinide
Ability to understand the requirements of the study and to provide informed consent
HbA1c, glycated hemoglobin; PCI, percutaneous coronary intervention.

Table 3 Exclusion criteria

Very tortuous coronary artery and/or severe calcification which is unsuitable for intravascular imaging
Subjects with severe renal dysfunction (estimated glomerular filtration rate < 40 mL/min/1.73 m²)
The absence of any atherosclerotic lesions in the non-target vessel
Those who take PCSK9 inhibitor
Current enrolment in another investing device or drug study
Pregnancy
PCSK9, proprotein convertase subtilisin/kexin type 9.
will be excluded due to the risk of NIRS/IVUS imaging. Subjects with baseline estimated glomerular filtration rate <40 mL/min/1.73 m², those without any atherosclerotic lesions in their non-culprit vessels and patients who are taking or are scheduled to receive proprotein convertase subxilisin/kexin type 9 will not be eligible.

Treatments and key procedures

After informed consent has been obtained, elective PCI will be conducted to treat culprit lesion after dual antiplatelet therapy consisting of aspirin and a P2Y12 inhibitor is commenced at least one week prior to PCI. All procedural decisions including the selection of device and adjunctive pharmacotherapy will be made according to the discretion of the individual PCI operator. Following the completion of PCI, guidewire will be inserted into the non-culprit vessel. NIRS/IVUS imaging will be advanced into the distal end of the non-culprit vessel artery and then automatically pullbacked at 2 mm/sec. The non-culprit vessel should have mild stenosis with percent diameter stenosis between 10–50%.

Dual antiplatelet therapy will be continued at maintenance doses (aspirin ≤100 mg/day and clopidogrel 75 mg/prasugrel 3.75 mg/ticagrelor 90 mg) for a duration that is determined by treating physicians, typically lifelong for aspirin and 6–12 months for clopidogrel/prasugrel/ticagrelor. Guideline-recommended medical therapy including beta-blockers and angiotensin converting enzyme inhibitors/angiotensin receptor blockers will be administered as appropriate. Adequate intensity of statin is used to achieve LDL-C below 70 mg/dL according to the Japan Atherosclerosis Society therapeutic guideline. Other lipid lowering therapies are allowed to use if LDL-C therapeutic goal is not achieved under statin therapy. PCSK9 inhibitor is prohibited in the current study.

As mentioned above, in the CGM-based glucose management group, CGM (FreeStyle Libre Pro®, Abbott, Chicago, Illinoi, the United States) and HbA1c measurement will be undertaken at baseline and 3, 6, 9 and 12 months following PCI. In the HbA1c-based glucose management group, HbA1c will be measured at baseline and 3, 6, 9 and 12 months after PCI, and CGM will be used at baseline and 12 months in a similar fashion (Figure 1).

With regard to the use of anti-diabetic drugs, in the CGM-guided glycemic control group, endocrinologist will select glucose lowering drugs to fulfill the following CGM-derived goals: (I) the frequency of hypoglycemia ≤0%, (II) the coefficient of variation <36% and (III) averaged glucose level between 70–180 mg/dL (6). If the frequency of hypoglycemia is over 10% and/or the averaged glucose level is more than 400 mg/dL, patients will be asked to visit within 1 month after CGM measurement. In the HbA1c-guided therapy group, the selection of glucose lowering agents will be made according to the discretion of each endocrinologist to achieve HbA1c <7.0%.

At 12 months following PCI, patients will be hospitalized to take follow-up coronary angiography and intravascular imaging study. NIRS/IVUS imaging in the non-culprit vessel will be conducted again in a similar fashion.

Biomarkers including proprotein convertase subxilisin/kexin type 9, fatty-acid binding protein 4 and 5, and caspase-3 and myeloperoxidase will be measured at baseline and 12 months.

Acquisition and analysis of NIRS/IVUS imaging

In all cases, operators will be encouraged to maximize the length of NIRS-IVUS pullback performed. The analyzed segment will be defined by the proximal and distal fiduciary sites. Technicians blinded to the treatment status of the patient and the timing of each individual pullback will perform the analysis. A matched arterial segment will be determined for measurement that contains the same proximal and distal side branch. Cross-sectional images, spaced 1 mm apart, will be selected for measurement. The leading edges of the lumen and the external elastic membrane (EEM) will be defined by manual planimetry. In each image, the plaque area will be calculated as the area between the two leading edges. The total atheroma volume (TAV) is calculated as the summation of plaque areas in each measured cross-sectional image within the segment, and subsequently normalized by the median number of images analyzed in the entire cohort to account for heterogeneity in segment length between subjects.

With regard to NIRS analysis, spectroscopic information obtained from raw spectra will be transformed into a probability of lipid core that will be mapped to a red-to-yellow color scale, with the low probability of lipid shown as red and the high probability of lipid shown as yellow. Analyses will be performed offline using the commercially available software (QIvus®, Medis, Leiden, The Netherland). Yellow pixels within the analyzed segment will be divided by all viable pixels to generate the lipid-core burden index (LCBI). The maximal value of LCBI for the analyzed segment will be recorded and used for comparison.
Safety

Based on the intention-to-treat the entire population, the OPTIMAL study will monitor safety by collecting the following adverse effects (AEs) during the trial: severe AEs regardless as to whether or not there is causal relationship between the AEs and the study; and relevant AEs such as hypoglycemia, bleeding and pains related to CGM use. The grade of severity, procedures, outcomes, and relationship to the study drug will be evaluated. The principal investigator will promptly report AEs to the study secretariat and to the Data and Safety Monitoring Board (DSMB), which consist of authorized endocrinologists, cardiologists, or neurologist with relevant expertise. The incident of withdrawal from the study will be also reported to the DSMB. The DSMB will then assess the incident and report the decision to the primary investigator. Auditing will be conducted annually.

Analysis of primary and secondary endpoints

Efficacy and safety analyses will be performed on the full analysis set, which includes all randomized patients. The primary analysis will be performed when all randomized subjects either have completed the scheduled study visits or have withdrawn early from the study. Analysis of the primary endpoint will be conducted with a linear mixed effects model. Analysis will be based on the intention-to-treat principle and patients will contribute to the group to which they were randomized. Patients with missing data for the primary end-point will be excluded from the primary analysis. The secondary analysis will be performed in the same manner as the primary analysis. All comparisons are planned and all P values will be two sided. P values <0.05 will be considered statistically significant. All statistical analyses will be performed using SAS software version 9.4 (SAS Institute, Cary, NC, USA).

Safety analyses

For analyses of safety outcomes, missing data will not be imputed, and adverse events will be summarized by treatment group using descriptive statistics. For analyses of
clinical endpoints, incidence of events will be summarized for each randomized treatment group.

Results

The primary endpoint is the normalized absolute change in TAV from baseline to 12 months. The secondary endpoints include (I) the absolute change in percent atheroma volume, (II) the percent change in lipid core burden index, (III) the change in coefficient variance measured by CGM, (IV) the association of change in atherogenic markers (proprotein convertase subxilisin/kexin type 9, fatty-acid binding protein 4 and 5, and caspase-3 and myeloperoxidase) with the normalized absolute change in TAV, (V) change in TAV under the use of specific anti-diabetic agents (dipeptidyl peptidase-4 inhibitors, sodium-glucose transport protein 2 inhibitors and glucagon-like peptide-1 agonists), and (VI) the frequency of hypoglycemia. NIRS/IVUS analysis is performed by two independent physicians who are blinded to patients’ information. The matched arterial segment, defined by the presence of a proximal and distal side branch, will be evaluated. With regard to IVUS analysis, in each cross-sectional image, the leading edges of the lumen and EEM will be manually traced. Lipid core burden index on NIRS imaging will be measured by commercially available software (QIVus®; Medis, Leiden, the Netherlands).

This is a superiority trial powered for the primary endpoint. Our previous randomized clinical trial (UMIN0000107) reported 24.7% reduction of coronary atheroma progression rate in early-stage type 2 diabetic patients with optimal control of glycemic variability, reflected by achieving a lower level of postprandial glucose (7). Considering that the response to anti-atherosclerotic therapies is diminished in the advanced type 2 diabetic subjects (8,9), we assume this anti-atherosclerotic efficacy would be half in our T2DM subjects. We estimate that 12.4% reduction of progression rate would occur in advanced T2DM patients who achieved better glycemic variability. 12.4% angiographical reduction of progression rate would correspond to 37.05 mm³ more reduction in atheroma volume (10). By adopting a common SD of 59, a total sample size of 82 patients would provide statistical power of 80% at a significance level of 5% for a two-sided t test. Anticipating a dropout rate of 10% at 12 months after PCI, a total of 90 patients should be recruited (45 per arm).

Discussion

Accumulating evidence suggests the importance of glycemic variability in the occurrence of macrovascular disease in T2DM subjects. Abrupt glycemic surge has been shown to induce oxidative stress and enhance endothelial cell apoptosis more potently compared to sustained hyperglycemia in T2DM patients (11,12). These atherogenic properties of glycemic variability have been supported by epidemiological and observational studies which consistently reported the association of diabetic macrovascular diseases with postprandial but not fasting hyperglycemia (13-16). In addition to these glycemic surges, hypoglycemia has been also shown to promote progression of atherosclerosis via triggering inflammation and endothelial dysfunctions (17,18). Collectively, these findings indicate the need for the clinically-applicable tool to accurately visualize glucose fluctuation and then select adequate glucose-lowering agents in subjects with T2DM.

The usefulness of CGM for the glycemic management of T2DM has been already reported by recent randomized controlled trials. CGM-based glycemic management has enabled to quantitatively evaluate glycemic variability, improve glycemic control and reduce the risk of hypoglycemia (6). Additionally, the mean amplitude of glycemic excursion, one of CGM-derived measures for glycemic variability, has been shown to associate with the progression of coronary atherosclerosis and its instability (19,20). This finding indicates the potential of CGM-based glycemic management to effectively modify the extent of glucose fluctuation, which may potentially lead to slowing atheroma progression.

The current study will employ a novel intravascular imaging catheter which combine intravascular ultrasound (IVUS) and near-infrared spectroscopy (NIRS). Serial IVUS imaging has been pivotal approach in outlining the anti-atherosclerotic effects of medical therapies within the arterial wall (21). NIRS imaging enables to quantitatively measure the degree of lipidic materials within coronary atheroma in vivo, which associates with future coronary events (22). The combination of IVUS and NIRS will provide additive information whether CGM-based glycemic management has any influence on both the quantity and quality of coronary atheroma in T2DM patients with CAD.

Conclusions

In conclusion, T2DM patients with CAD are still the high-risk subjects who more frequently have macrovascular diseases despite guideline-recommended medical therapies. The collaboration of CGM use with serial NIRS/IVUS imaging will explore whether less atheroma progression
can be achieved under CGM-based glycemic management, compared to HbA1c-based approach. These data will serve as an important prelude to the future clinical outcome studies testing the efficacy of anti-glycemic therapies with CGM.

**Acknowledgments**

The authors thank Miss Maki Maruki and Miss Emi Kanai for their kind and excellent assistance at the Department of Cardiovascular Medicine and the Division of Atherosclerosis and Diabetes of the National Cerebral and Cardiovascular Center.

**Funding:** This trial is supported by Japan Agency for Medical Research and Development (grant number: 18ek0210104h0001, tel: +81-3-6870-2200).

**Footnote**

**Conflicts of Interest:** The authors have no conflicts of interest to declare.

**Ethical Statement:** The protocol was approved by the institutional ethics committees (M30-152), and written informed consent will be obtained from all study participants prior to entering the study. The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

**References**


Table S1 Study organization

<table>
<thead>
<tr>
<th>Role</th>
<th>Names</th>
</tr>
</thead>
<tbody>
<tr>
<td>Principal investigator</td>
<td>Yu Kataoka</td>
</tr>
<tr>
<td>Steering Committee</td>
<td>Kiminori Hosoda, Yoshihiro Miyamoto,</td>
</tr>
<tr>
<td></td>
<td>Hisashi Makino, Teruo Noguchi, Satoshi</td>
</tr>
<tr>
<td></td>
<td>Yasuda</td>
</tr>
<tr>
<td>Executive Committee</td>
<td>Masaki Matsubara, Miki Matsuo, Yoko</td>
</tr>
<tr>
<td></td>
<td>Ohata, Ryo Koezuka, Tamiko Tamanaha,</td>
</tr>
<tr>
<td></td>
<td>Tsutomu Tomita, Kyoko Koumo, Michio</td>
</tr>
<tr>
<td></td>
<td>Noguchi, Cheol Son, Yasuhide Asaumi</td>
</tr>
<tr>
<td>Statistical analysis</td>
<td>Kunihiro Nishimura</td>
</tr>
<tr>
<td>Monitoring</td>
<td>Kazuhiro Nakao</td>
</tr>
<tr>
<td>Data center and management</td>
<td>Satoshi Honda</td>
</tr>
<tr>
<td>Data and safety monitoring board</td>
<td>Hiroki Yoshihara, Kazuo Washio, Makoto</td>
</tr>
<tr>
<td></td>
<td>Watanabe</td>
</tr>
<tr>
<td>Trials secretariat</td>
<td>Emi Kanai, Maki Maruki</td>
</tr>
</tbody>
</table>